ZD6474 (ZACTIMA) is an orally available, selective inhibitor of tyrosine kinases coding for vascular endothelial growth factor receptor, epidermal growth factor receptor and RET (REarranged during Transfection). ZD6474 inhibits the growth of a broad range of established human tumor xenografts, including those from prostate, breast, ovary and lung. 1 In addition, we have recently shown that ZD6474 induced growth arrest and apoptosis of gastrointestinal stromal tumor cells via inhibition of c-KIT signaling. 2 This study explored the effect of ZD6474 on a variety of human leukemia cell lines with defined genetic abnormalities. ZD6474 induced growth arrest and apoptosis of EOL-1, MV4-11 and Kasumi-1 cells, which posseses activating mutations in platelet-derived growth factor receptor a (PDGFRa), FMS-like tyrosine kinase 3 (FLT3) and c-KIT, respectively (Table 1) . ZD6474 effectively inhibited phosphorylation of PDGFR, FLT3, and c-KIT in these leukemia cells (Figure 1a ). In addition, ZD6474 was active against freshly isolated acute myeloid leukemia (AML) cells that had mutations in the FLT3 gene as measured by colony forming assay (Table 2) . Additional investigations revealed that ZD6474 blocked the downstream signaling pathways including extracellular signalregulated kinase (ERK) signaling in EOL-1 cells (Figure 1b) . Further studies examined the antileukemic activity of AZD6244 (ARRY-142886), 3 a novel inhibitor of mitogen-activated protein kinase /ERK signaling. The drug synergistically enhanced the . After 1 h, the cells were harvested and proteins were extracted and subjected to Western blot analysis. The membrane was sequentially probed with anti-phospho-Akt (Ser473), anti-phospho-STAT3 (Tyr705), anti-phospho-ERK (Tyr202/Tyr204), anti-Akt, anti-STAT3 and anti-ERK antibodies, and band intensities were measured using densitometry.
Letters to the Editor ability of ZD6474 to induce growth arrest and apoptosis of EOL-1 cells in conjunction with further downregulation of p-ERK (Figures 2a-d) .
Clinical studies showed that the remission in AML patients elicited by sunitinib, an FLT3 kinase inhibitor, was partial and of short duration, 4 suggesting that the addition of other anticancer compounds may be required. Recently, we have shown that blockade of Akt/mTOR signaling by rapamycin synergistically enhanced sunitinib-mediated growth inhibition of leukemia cells. 5 Taken together, concomitant administration of the FLT3 Letters to the Editor kinase inhibitor and downstream signal pathway inhibitor such as rapamycin, as well as AZD6244, may be a potential treatment strategy. In summary, ZD6474 may be an effective treatment for individuals with AML that possess mutations in receptor tyrosine kinase genes. In addition, the combined administration of ZD6474 and AZD6244 to patients with AML warrants further investigation.
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity Angiogenesis is an absolute requirement for tumor growth and metastasis, and is an attractive target for biologically based cancer therapies. Vascular endothelial growth factor (VEGF, VEGF-A) is one of the most potent promoters of angiogenesis whose functions are mainly mediated through the tyrosine kinase receptor VEGFR-2 (also known as KDR or Flk-1).
Comparable to solid tumors, there is growing evidence that the VEGF/VEGFR2 signaling pathway plays an important role in leukemic cell growth. [1] [2] [3] [4] Clinical trials with VEGF inhibition in a variety of malignancies are ongoing. The best-studied and most advanced approach to VEGF inhibition is the recombinant humanized monoclonal antibody bevacizumab (BV). We have treated patients with relapsed or refractory acute myeloid leukemia (AML), not qualifying for further intensive cytotoxic chemotherapy, in order to investigate single agent BV in AML. Nine patients were treated between May 2005 and May 2006. All patients signed informed consent before enrollment.
A summary of baseline patient characteristics is shown in Table 1 . Patients were between 46 and 81 years old (median: -1 mM) or control diluent. After 24 h, cells were exposed to either AZD6244 (0.25 mM) or control diluent for 15 min. Cells were harvested, incubated with anti-p-ERK antibody for 30 min at room temperature, and analyzed by flow cytometry. Results represent one of the experiments performed twice in duplicate plate. p-ERK-positive population was quantified using the CellQuest software package. For figure see previous page.
